In an initial study enrolling patients with stage IV NSCLC with MET exon 14 skipping mutations and treated with crizotinib or cabozantinib, Paik et al reported a complete response in one patient treated with cabozantinib [58]. This evidence concerns the gene MET and non-small cell lung carcinoma.